Search Results



Your search for all items matches 121 pages

Showing 1 - 50


gastroesophageal cancer
gastrointestinal cancer

Anti–PD-1 Immunotherapy in Previously Treated Gastric Cancer

As reported in JAMA Oncology by Fuchs et al, pembrolizumab (Keytruda) showed activity in patients with previously treated advanced gastric and gastroesophageal junction cancer in the phase II KEYNOTE-059 trial. Study Details In the study, 259 patients from sites in 16 countries who had disease...

solid tumors
colorectal cancer
gastrointestinal cancer

Triplet Therapy Poses a Triple Threat to BRAF-Mutated Colorectal Cancers

Triplet therapy that inhibits the BRAF, MEK, and epidermal growth factor receptor (EGFR) pathways appears promising in BRAF-mutated colorectal cancer, a malignancy that typically does not respond to BRAF inhibition alone. Early results from the BEACON CRC study showed a 48% response rate and an...

gastrointestinal cancer
colorectal cancer

Studies Explore Colon Tumor Sidedness, Lung Radiation Dose in Esophageal Cancer, Pembrolizumab in Liver Cancer, and More

Along with full coverage of key presentations from the 2018 Gastrointestinal Cancers Symposium, The ASCO Post brings our readers this additional news roundup.  Side Matters in Colon Cancer One of the studies included in the global IDEA trial, which compared 3 vs 6 months of adjuvant chemotherapy in ...

solid tumors
gastrointestinal cancer

Lutetium Lu-177 Dotatate in Gastroenteropancreatic Neuroendocrine Tumors

On January 26, 2018, the radiolabeled somatostatin analog lutetium Lu-177 dotatate (Lutathera) was approved for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors, in adults.1,2 Supporting...

issues in oncology
gastrointestinal cancer

Rehospitalization Patterns After Gastrointestinal Cancer Hospitalizations

In a study reported in the Journal of Oncology Practice, Manzano et al found that unplanned rehospitalization within 30 days after gastrointestinal (GI) cancer hospitalization was more likely after medical vs surgical index hospitalizations among older patients. Some risk factors for...

gastrointestinal cancer

EXPERT POINT OF VIEW: Stephen Leong, MD

STEPHEN LEONG, MD, of the University of Colorado Comprehensive Cancer Center, Aurora, discussed the RAINFALL findings at the symposium, commenting, “The study did meet its primary endpoint of progression-free survival; however, it was disappointing not to see a benefit in overall survival or...

gastrointestinal cancer

Ramucirumab/Chemotherapy in Gastric Cancer: ‘Positive’ Trial but Insufficient Benefit

BASED ON EFFICACY seen in the second-line setting for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma, ramucirumab (Cyramza) was evaluated as first-line therapy in the international phase III RAINFALL trial. Although the study met its primary endpoint, with a 25%...

solid tumors
gastrointestinal cancer

FDA Approves Radiopharmaceutical for Rare Gastrointestinal Cancers

On January 26, 2018, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug is indicated for adult patients with somatostatin receptor–positive GEP-NETs. GEP-NETs can be...

pancreatic cancer
gastrointestinal cancer

FDA Approves Lutetium Lu-177 Dotatate for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

On January 26, the U.S. Food and Drug Administration (FDA) approved lutetium Lu-177 dotatate (Lutathera) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first time a radiopharmaceutical has been approved for the treatment of GEP-NETs. Lutetium Lu-177...

gastrointestinal cancer

Nodal Stage Migration and Prognosis in Anal Cancer

  In a study reported in The Lancet Oncology, Sekhar and colleagues found that the increasing proportion of lymph node–positive disease associated with enhanced detection techniques has led to nodal stage migration in anal cancer, which may reduce prognostic discrimination on the basis of lymph...

gastroesophageal cancer
gastrointestinal cancer

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implications for survival, and the link to a deficiency in mismatched repair genes (Abstract 9).

gastroesophageal cancer
gastrointestinal cancer

Manish A. Shah, MD, on Gastric Cancer: Results From the RAINFALL Trial

Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma (Abstract 5).

gastrointestinal cancer

Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial

Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer (Abstract 4).

gastrointestinal cancer

Khaldoun Almhanna, MD, MPH, on Gastric Cancer: Results From the CCOG 1102 Trial

Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, discusses the long-term outcome of a phase III study that explored the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer (Abstract 1).

breast cancer
skin cancer
issues in oncology
gastrointestinal cancer

Study Finds Increased Risk in Common Cancers in Female Night Shift Workers

In 2007, the International Agency for Research on Cancer classified shift work with circadian disruption or chronodisruption as a probable human carcinogen. Now, a meta-analysis investigating whether long-term shift work increases the risks of common cancers in women has found that, overall, night...

gastroesophageal cancer
gastrointestinal cancer

Updated Data in KEYNOTE-061: Pembrolizumab in Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma

The phase III KEYNOTE-061 trial investigating pembrolizumab (Keytruda) as a second-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma did not meet its primary endpoint of overall survival (OS) (hazard ratio [HR] = 0.82, 95% confidence interval [CI] = ...

gastroesophageal cancer
gastrointestinal cancer

Update on Phase III JAVELIN Gastric 300 Trial of Avelumab in Pretreated Advanced Gastric Cancer

On November 28, Merck KGaA and Pfizer announced that the phase III JAVELIN Gastric 300 trial did not meet its primary endpoint of superior overall survival with single-agent avelumab (Bavencio) compared with physician's choice of chemotherapy. The trial investigated avelumab as a third-line...

solid tumors
gastrointestinal cancer

Pembrolizumab in Advanced Gastric Cancer

On September 22, 2017, pembrolizumab (Keytruda) was granted accelerated approval for treatment of recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma with tumors expressing programmed cell death ligand 1 (PD-L1), as determined by a U.S. Food and Drug...

solid tumors
gastrointestinal cancer
gastroesophageal cancer

Metastatic Gastric Cancer: Dual HER2-Targeting Study Does Not Meet Primary Endpoint

Dual HER2 targeting in metastatic gastric and gastroesophageal junction cancers did not significantly improve outcomes over trastuzumab (Herceptin) alone—both in combination with chemotherapy—according to the results of the phase III JACOB study reported at the 2017 European Society for Medical...

gastrointestinal cancer

Adding Targeted Agent to Chemotherapy in Second-Line Treatment of Advanced Gastric Cancer

In the Asian phase III GOLD trial reported in The Lancet Oncology, Bang et al found that the addition of olaparib (Lynparza) to paclitaxel did not significantly improve overall survival among patients with previously treated advanced gastric cancer, including those with...

gastrointestinal cancer

Quick Takes on Studies in Noncolorectal Gastrointestinal Cancers

In this roundup, The ASCO Post offers a glance at key findings from studies in noncolorectal gastrointestinal malignancies presented at the European Society for Medical Oncology (ESMO) 2017 Congress from investigators around the world. Docetaxel-Based Triplet in Gastric Cancer The superiority of...

gastrointestinal cancer

EXPERT POINT OF VIEW: Eric Van Cutsem, MD, PhD

Invited discussant Eric Van Cutsem, MD, PhD, of University Hospitals Leuven, Belgium, commented that both ATTRACTION-02 and KEYNOTE-059 suggest that anti-PD [programmed cell death protein] antibodies have activity in advanced gastric cancer, but their findings differed with regard to the impact of ...

gastrointestinal cancer

Anti–PD-1 Agents Gaining Momentum in Gastric Cancer

In updates of two important studies in metastatic gastric cancer reported at the European Society for Medical Oncology (ESMO) 2017 Congress, nivolumab -(Opdivo) and pembrolizumab (Keytruda) demonstrated activity—but to varying degrees and with some nuances. “Anti-PD [programmed cell death protein]...

gastrointestinal cancer

Survival in Patients Treated With Adjuvant Chemoradiotherapy After Resection of Gastric Cancer

In the CALGB 80101/Alliance trial, no difference in overall survival was found for adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil (ECF) vs fluorouracil and leucovorin (5-FU/LV) after curative resection of gastric cancer. The findings were reported in the Journal of Clinical ...

gastrointestinal cancer

Immunotherapy for Previously Treated Advanced Gastric Cancer

In an Asian phase III trial (ONO-4538-12, ATTRACTION-2) reported in The Lancet, Kang et al found that nivolumab (Opdivo) produced an improvement in overall survival vs placebo in patients with advanced gastric or gastroesophageal junction cancer who had disease refractory to or who were intolerant...

gastrointestinal cancer

Nivolumab Approved in Japan for Unresectable Advanced or Recurrent Gastric Cancer That Has Progressed After Chemotherapy

On September 22, Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved nivolumab (Opdivo) for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy. This approval was based on the phase III ...

gastrointestinal cancer

Addition of MET Inhibitor to First-Line Chemotherapy in Advanced Gastric Cancer

The phase III RILOMET-1 trial showed no survival benefit of adding the MET inhibitor rilotumumab to first-line epirubicin, cisplatin, and capecitabine in patients with advanced MET-positive gastric or gastroesophageal junction adenocarcinoma. These results were reported in The Lancet Oncology by...

gastrointestinal cancer

FDA Grants Accelerated Approval to Pembrolizumab for Advanced Gastric Cancer

On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for patients with recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express programmed cell death ligand 1 (PD-L1) as...

gastrointestinal cancer

Regorafenib in Hepatocellular Carcinoma Previously Treated With Sorafenib

On April 27, 2017, the indications for regorafenib (Stivarga) were expanded to include treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib (Nexavar).1,2 Supporting Efficacy Data The new approval was based on the finding of improved overall survival...

gastrointestinal cancer

ESMO 2017: Pembrolizumab Shows Promising Response Rate in Pretreated Metastatic Gastric Cancer

Pembrolizumab (Keytruda) has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract LBA28_PR). The expected...

gastrointestinal cancer

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

In a single-center experience reported in JAMA Surgery, Eng et al found that an increased intraoperative fluid rate was associated with increased perioperative morbidity in patients with peritoneal cancer undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Study...

lung cancer
gastrointestinal cancer

Health-Related Quality of Life With Everolimus vs Placebo in Patients With Neuroendocrine Tumors

As reported in The Lancet Oncology by Pavel et al, no significant difference in deterioration of health-related quality of life was observed with everolimus (Afinitor) vs placebo in the phase III RADIANT-4 trial, which included patients with advanced nonfunctional well-differentiated...

gastrointestinal cancer

Relationship Between Molecular Subtypes of Gastric Cancer and Prognosis

In 2014, The Cancer Genome Atlas (TCGA) project discovered there are four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability, genomically stable, and chromosomal instability. However, their clinical significance is unknown.  Now, a study by Bo Hwa Sohn, PhD,...

gastrointestinal cancer

Positioning 177-Lu-Dotatate Therapy and 68-Ga-Dotatate Scans in Management of Neuroendocrine Tumors

The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine,1 have been met with great interest by clinicians who treat neuroendocrine tumors. In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium-177-Dotatate...

gastrointestinal cancer

‘Sidedness’ in Colon Cancer: Using the Data in the Clinic

The evidence from clinical trials has established that “side matters” when it comes to colorectal cancer outcomes. How do clinicians use this information in their practices? Christina Wu, MD, of Emory University, shared her thoughts with attendees at the 2017 Debates and Didactics in Hematology and ...

gastrointestinal cancer

Adding First-Line Selective Internal Radiotherapy to Chemotherapy in Patients With Liver Metastases From Colorectal Cancer

A meta-analysis of three randomized trials (FOXFIRE, SIRFLOX, and FOXFIRE-Global) indicates no overall survival benefit of adding first-line selective internal radiotherapy to chemotherapy in patients with liver metastases from colorectal cancer. The findings were reported by Wasan et al in The...

breast cancer
leukemia
supportive care
gastrointestinal cancer

FDA Actions Yield Extended Approvals of Novel Agents, Advisory Committee Votes Favorably on Two Biosimilars and Pediatric Indication for CAR T-Cell Therapy

DURING JULY, the U.S. Food and Drug Administration (FDA) and its Oncologic Drugs Advisory Committee (ODAC) made a number of approvals and recommendations on a variety of oncology products.  Neratinib  ON JULY 1 7, the FDA approved neratinib (Nerlynx) for the extended adjuvant treatment of adult...

gastrointestinal cancer

Classifying Gastric Cancers by Subtype May Provide Tailored Treatment Options

Gastric cancer is the third leading cause of cancer death in both men and women worldwide. In 2014, The Cancer Genome Atlas (TCGA) project discovered there are four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and...

gastrointestinal cancer

ESMO World GI 2017: Study Explores Association of Mediterranean Diet Components With Advanced Colorectal Polyps

The benefits of a Mediterranean diet are well known when it comes to colorectal protection, but it’s hard to know specifically what elements of the diet are the healthiest. Now a new study, presented by Fliss Isakov et al at the ESMO 19th World Congress on Gastrointestinal Cancer, suggests...

gastrointestinal cancer

Some Patients With Stage III Low-Risk Colon Cancer May Require Less Oxaliplatin Therapy

Patients with stage III colon cancer considered at low risk for recurrence may be treated effectively—and incur less neurotoxicity—with 3 months of an oxaliplatin-based regimen as compared with the standard 6 months, according to the results of the International Duration Evaluation of Adjuvant...

gastrointestinal cancer

Expert Point of View: Daniel G. Coit, MD

“While these results are clearly superior to historical controls, the study prompts a number of questions,” session moderator, ­Daniel G. Coit, MD, a surgical oncologist at Memorial Sloan Kettering Cancer Center in New York, commented in an interview. “Nearly half of the patients received systemic ...

gastrointestinal cancer

Hyperthermic Intraperitoneal Chemoperfusion May Be Efficacious for Peritoneal Metastases

Hyperthermic intraperitoneal chemoperfusion is efficacious when used as part of multimodality therapy for low-volume peritoneal metastases of gastric cancer, suggests a prospective single-arm phase II trial.1 Among the 19 patients enrolled, all of whom had stage IV disease with ­either...

gastrointestinal cancer

10-Year Outcomes With Two Dose Levels of Imatinib in Unresectable or Metastatic GIST

Casali et al have reported 10-year progression-free and overall survival rates among patients with locally advanced unresectable or metastatic gastrointestinal stromal tumors (GISTs) receiving imatinib at 400 or 800 mg/d in the phase III European Organisation for Research and Treatment of Cancer,...

gastrointestinal cancer
colorectal cancer
issues in oncology

Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate

The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...

head and neck cancer
lymphoma
gastrointestinal cancer

Protein Component of the Epstein-Barr Virus May Promote the Development of Cancer

After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms. About one-third of infected teenagers and young adults nevertheless develop infectious mononucleosis, which usually wears off after a few weeks. ...

pancreatic cancer
gastrointestinal cancer
colorectal cancer

‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The University of Texas MD...

gastrointestinal cancer

Expert Point of View: Heinz-Josef Lenz, MD

Heinz-Josef Lenz, MD, of the University of Southern California in Los Angeles, said the results of the ONO-4538 trial were impressive in light of this challenging patient population. “You see a significant benefit in a highly refractory gastric cancer population,” he said. Dr. Lenz cautioned:...

gastrointestinal cancer

Nivolumab, as Salvage, Improves Overall Survival in Gastric Cancer

Gastric cancer can apparently be added to the growing list of malignancies for which drugs targeting the programmed cell death protein 1 (PD‑1) receptor are effective, according to the results of the phase III ONO-4538 investigation conducted in Asia and presented at the 2017 Gastrointestinal...

gastrointestinal cancer

Small-Intestine GIST Treated Surgically Associated With Better Prognosis in Younger Patients

Gastrointestinal stromal tumors (GIST) arise is the wall of the digestive tract and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. In an article published by Fero et al in...

gastrointestinal cancer

Masanori Terashima, MD, PhD, on Gastric Cancer: Results of the JCOG1001 Trial

Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).

Advertisement



Advertisement


Advertisement